Fulgent Genetics Stock Buy Hold or Sell Recommendation
FLGT Stock | USD 21.70 0.01 0.05% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Fulgent Genetics is 'Hold'. Macroaxis provides Fulgent Genetics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding FLGT positions. The advice algorithm takes into account all of Fulgent Genetics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Fulgent Genetics' buy or sell advice are summarized below:
Real Value 25.92 | Target Price 36.5 | Hype Value 21.46 | Market Value 21.7 | Naive Value 22.41 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Fulgent Genetics given historical horizon and risk tolerance towards Fulgent Genetics. When Macroaxis issues a 'buy' or 'sell' recommendation for Fulgent Genetics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Fulgent |
Execute Fulgent Genetics Buy or Sell Advice
The Fulgent recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Fulgent Genetics. Macroaxis does not own or have any residual interests in Fulgent Genetics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Fulgent Genetics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Fulgent Genetics Trading Alerts and Improvement Suggestions
Fulgent Genetics generated a negative expected return over the last 90 days | |
The company reported the previous year's revenue of 289.21 M. Net Loss for the year was (167.82 M) with profit before overhead, payroll, taxes, and interest of 366.9 M. | |
About 32.0% of the company shares are held by company insiders | |
Latest headline from MacroaxisInsider: Disposition of 865 shares by Paul Kim of Fulgent Genetics at 29.33 subject to Rule 16b-3 |
Fulgent Genetics Returns Distribution Density
The distribution of Fulgent Genetics' historical returns is an attempt to chart the uncertainty of Fulgent Genetics' future price movements. The chart of the probability distribution of Fulgent Genetics daily returns describes the distribution of returns around its average expected value. We use Fulgent Genetics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Fulgent Genetics returns is essential to provide solid investment advice for Fulgent Genetics.
Mean Return | -0.45 | Value At Risk | -4.73 | Potential Upside | 3.83 | Standard Deviation | 2.41 |
Return Density |
Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Fulgent Genetics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Fulgent Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Fulgent Genetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fulgent Genetics backward and forwards among themselves. Fulgent Genetics' institutional investor refers to the entity that pools money to purchase Fulgent Genetics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 263.3 K | Ameriprise Financial Inc | 2023-12-31 | 250.6 K | Northern Trust Corp | 2023-12-31 | 231.4 K | Goldman Sachs Group Inc | 2023-12-31 | 204.8 K | Citadel Advisors Llc | 2023-09-30 | 193 K | Norges Bank | 2023-12-31 | 176.5 K | Bank Of New York Mellon Corp | 2023-12-31 | 155.9 K | Bridgeway Capital Management, Llc | 2023-12-31 | 153.7 K | Divisadero Street Capital Management, Lp | 2023-12-31 | 137.3 K | Blackrock Inc | 2023-12-31 | 3.8 M | Dimensional Fund Advisors, Inc. | 2023-12-31 | 1.4 M |
Fulgent Genetics Cash Flow Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Investments | (27.9M) | (289.9M) | (460.9M) | (261.3M) | 38.9M | 40.8M | |
Change In Cash | 5.2M | 75.5M | 77.5M | (85.4M) | 18.0M | 10.6M | |
Free Cash Flow | 4.2M | 104.1M | 514.7M | 234.7M | 4.8M | 4.6M | |
Depreciation | 2.1M | 3.0M | 11.0M | 32.7M | 31.8M | 33.3M | |
Other Non Cash Items | 1.5M | 8.0M | 16.0M | 43.5M | 105.8M | 111.1M | |
Capital Expenditures | 1.3M | 36.5M | 23.8M | 18.8M | 22.2M | 12.9M | |
Net Income | (411K) | 214.3M | 506.2M | 141.9M | (167.8M) | (159.4M) | |
End Period Cash Flow | 12.0M | 87.4M | 164.9M | 79.5M | 97.5M | 50.9M | |
Change To Netincome | 4.2M | 8.7M | 22.9M | 75.5M | 86.8M | 91.1M | |
Change Receivables | (2.0M) | (839K) | (178.5M) | 42.3M | 38.1M | 40.0M |
Fulgent Genetics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Fulgent Genetics or Health Care Providers & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Fulgent Genetics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Fulgent stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.73 | |
β | Beta against NYSE Composite | 2.17 | |
σ | Overall volatility | 2.46 | |
Ir | Information ratio | -0.24 |
Fulgent Genetics Volatility Alert
Fulgent Genetics exhibits very low volatility with skewness of -0.22 and kurtosis of 1.0. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Fulgent Genetics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Fulgent Genetics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Fulgent Genetics Fundamentals Vs Peers
Comparing Fulgent Genetics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Fulgent Genetics' direct or indirect competition across all of the common fundamentals between Fulgent Genetics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Fulgent Genetics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Fulgent Genetics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Fulgent Genetics by comparing valuation metrics with those of similar companies.
Better Than Average | Worse Than Average | Compare Fulgent Genetics to competition |
Fundamentals | Fulgent Genetics | Peer Average |
Return On Equity | -0.15 | -0.31 |
Return On Asset | -0.0347 | -0.14 |
Profit Margin | (0.58) % | (1.27) % |
Operating Margin | (0.47) % | (5.51) % |
Current Valuation | 235.34 M | 16.62 B |
Shares Outstanding | 29.78 M | 571.82 M |
Shares Owned By Insiders | 31.76 % | 10.09 % |
Shares Owned By Institutions | 49.38 % | 39.21 % |
Number Of Shares Shorted | 611.22 K | 4.71 M |
Price To Earning | 3.95 X | 28.72 X |
Price To Book | 0.57 X | 9.51 X |
Price To Sales | 2.23 X | 11.42 X |
Revenue | 289.21 M | 9.43 B |
Gross Profit | 366.9 M | 27.38 B |
EBITDA | (43.54 M) | 3.9 B |
Net Income | (167.82 M) | 570.98 M |
Cash And Equivalents | 515.4 M | 2.7 B |
Cash Per Share | 17.03 X | 5.01 X |
Total Debt | 14.91 M | 5.32 B |
Debt To Equity | 0.03 % | 48.70 % |
Current Ratio | 5.29 X | 2.16 X |
Book Value Per Share | 38.31 X | 1.93 K |
Cash Flow From Operations | 27 M | 971.22 M |
Short Ratio | 1.93 X | 4.00 X |
Earnings Per Share | (5.63) X | 3.12 X |
Price To Earnings To Growth | 1.32 X | 4.89 X |
Target Price | 26.67 | |
Number Of Employees | 1.18 K | 18.84 K |
Beta | 1.45 | -0.15 |
Market Capitalization | 645.56 M | 19.03 B |
Total Asset | 1.27 B | 29.47 B |
Retained Earnings | 633.17 M | 9.33 B |
Working Capital | 434.83 M | 1.48 B |
Note: Disposition of 865 shares by Paul Kim of Fulgent Genetics at 29.33 subject to Rule 16b-3 [view details]
Fulgent Genetics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Fulgent . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Accumulation Distribution | 3408.46 | |||
Daily Balance Of Power | 0.0204 | |||
Rate Of Daily Change | 1.0 | |||
Day Median Price | 21.92 | |||
Day Typical Price | 21.84 | |||
Price Action Indicator | (0.21) | |||
Period Momentum Indicator | 0.01 |
About Fulgent Genetics Buy or Sell Advice
When is the right time to buy or sell Fulgent Genetics? Buying financial instruments such as Fulgent Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 36.7M | 58.4M | 49.1M | 51.6M | Total Assets | 1.3B | 1.4B | 1.3B | 1.3B |
Use Investing Ideas to Build Portfolios
In addition to having Fulgent Genetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Industrials ETFs Thematic Idea Now
Industrials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Industrials ETFs theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrials ETFs Theme or any other thematic opportunities.
View All Next | Launch |
Check out Fulgent Genetics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Fulgent Stock analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Transaction History View history of all your transactions and understand their impact on performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.63) | Revenue Per Share 9.71 | Quarterly Revenue Growth 0.041 | Return On Assets (0.03) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.